Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

What SmithOnStocks Is All About
It is traditional at the start of the year to go over stock picks for the…
Read more…

NovaBay: Data from Phase II Trial of Auriclosene in Urinary Catheter Blockage and Encrustation is Imminent (NBY, $1.40)

Company Overview and Purpose of the Report
NovaBay (NBY) will be reporting the results of three Phase II clinical trials involving…
Read more…

Thoughts on the Growing Crisis of Bacterial Resistance to Antibiotics

Investment Overview
We hear constantly from the media about problems with bacterial resistance to antibiotics. I think that this is an…
Read more…

NovaBay: Topline Data from Two Phase IIb Trials Presents an Asymmetric Investment Opportunity in 2013 (NBY, $1.24)

Introduction
NovaBay (NBY) is focused on the development of novel anti-microbial products that are topically applied as gels, liquid solutions and…
Read more…

NovaBay Swings for the Fences with NVC-422 Trial In Viral Conjunctivitis

Investment Thesis
Although NovaBay is a small company as judged by its $43 million market capitalization, it is complex to analyze.…
Read more…

Focusing on the Impetigo Indication for NVC-422 (NBY, $1.29)

Investment Thesis
Although NovaBay(NBY) is a small company as judged by its $37 million market capitalization, it is complex to analyze.…
Read more…

Initiation of Coverage on NovaBay with a Buy

Introduction

I have just written a new report on NovaBay (NBY) called NovaBayís Robust Clinical Pipeline Approaches Critical Clinical Trial Results…
Read more…

NovaBay's Robust Clinical Pipeline Approaches Critical Clinical Trial Results in 2013

Investment Thesis
NovaBay has just received approval in the US for its first product NeutroPhase and will be commercializing it throughout…
Read more…